EML4 and neoplasm: The combination of an ALK TKI with HSP90 inhibition not only yielded synergism in Ba/F3 cells expressing EML4-ALK V1, but also induced apoptosis in vitro and tumour regression in vivo of patient-derived cells expressing V1 [33,91].